Novo Nordisk Rebrands as Novo While Morgan Stanley Turns Bearish on Semaglutide Cliff

Novo Nordisk rebrands to "Novo" amid a 16% YTD share decline, a Morgan Stanley downgrade to Underweight and looming semaglutide patent expiry.

Novo Nordisk has unveiled a sweeping corporate identity overhaul, shortening its global brand to simply "Novo" and refreshing its visual language — including a traditional bull logo that now faces right instead of left. The legal entity Novo Nordisk A/S remains unchanged, and CEO Mike Doustdar is steering the initiative under the tagline "Lasting Health Starts Now," with an internal culture program dubbed "The Novo Way" rolled out across a workforce of more than 67,000.

The rebrand lands at an awkward moment. The Danish drugmaker's shares have shed 15% since the start of the year, though they have steadied of late and were quoted at EUR 37.45. Competition with Eli Lilly over GLP-1 weight-loss treatments remains fierce, and management is banking on the oral tablet version of Wegovy to shift the narrative — a product that had already generated more than three million US prescriptions by June.

Clinical Momentum and Setbacks in Equal Measure

Progress on the pipeline cuts both ways. In the Phase 3 STEP Young trial involving children under twelve, 40.4% of participants receiving weekly treatment plus lifestyle support brought their body-mass index below the obesity threshold after 68 weeks. Not a single participant in the placebo arm managed the same. Full data are slated for presentation at ObesityWeek in Washington in mid-November.

Yet the broader development picture has taken hits. Novo Nordisk halted Phase 3 trials of ziltivekimab last Wednesday, souring investor sentiment, and the combination drug CagriSema failed to demonstrate non-inferiority against rival tirzepatide in the REDEFINE 4 study — delivering 23.0% weight loss over 84 weeks versus tirzepatide's 25.5%.

Morgan Stanley Flips to Underweight

Adding to the pressure, Morgan Stanley downgraded the stock on 11 September from "Equal-weight" to "Underweight," citing a muted medium-term growth outlook and the looming patent expiry on semaglutide. The bank's price target of DKK 250 implies downside of more than 10%.

The crux of the concern: semaglutide, the active ingredient behind blockbusters Ozempic and Wegovy, accounted for roughly 75% of group revenue in 2026. Patent protection is set to lapse in Europe and the US in the early-to-mid 2030s. Morgan Stanley's own modelling assumes semaglutide will still contribute 59% of revenue in 2031 — precisely when the consequences of exclusivity loss begin to bite.

A proprietary survey of 200 US primary-care physicians reinforces the bear case, pointing to market-share losses for Novo Nordisk over the next 18 months — chiefly to Eli Lilly's Zepbound, Mounjaro and Foundayo, and from 2027 additionally to the rival drug retatrutide. Prescription data also reveal cooling growth for the Wegovy pill after a strong first half of 2026, with analysts reckoning that Eli Lilly has already captured the bulk of Medicare patients through its so-called Bridge programme.

The market reaction was swift: the stock fell 2.6% on Friday to close at EUR 37.05. Over the week the decline totals 6.9%, and across 30 days it stands at 5.9%. Year-to-date, the shares are down 16%. An RSI of 34.1 signals a technically oversold condition, though that alone offers no confirmation of a trend reversal.

Internal Mobilisation Ahead of Capital Markets Day

Novo Nordisk is responding internally to the mounting pressure. According to Bloomberg, the company summoned staff to a townhall on 15 September to discuss the group's "next chapter" — just days before its Capital Markets Day in London on 21 September. Investors will be watching closely for strategic answers, particularly regarding growth prospects beyond the current decade.

The decision to scrap two ziltivekimab studies also weighed on sentiment: an independent data monitoring committee deemed the prospects of the HERMES and ATHENA trials unlikely, following disappointment with the earlier ZEUS study. Novo Nordisk announced a non-cash impairment for the third quarter as a result, but stressed that its operating profit guidance for 2026 remains unaffected. The sole remaining trial for the drug, ARTEMIS, continues as an acute treatment after heart attacks, with data expected in the first half of 2027.

Core Business Holds Firm Despite Headwinds

For all the negative headlines, the underlying business remains solid. In the second quarter of 2026, Novo Nordisk posted a net profit of DKK 21.0 billion and free cash flow of DKK 42.5 billion, while adjusted operating profit rose 11% in constant currencies. The Wegovy pill captured roughly 90% of the US oral obesity-drug market and surpassed five million prescriptions worldwide.

For the full year, the group now anticipates adjusted revenue growth of between 0% and minus 6% at constant exchange rates, citing lower realised prices, reduced Medicaid coverage for obesity treatments, and the loss of semaglutide exclusivity in Canada and Brazil as drags. Meanwhile, Novo Nordisk is pressing ahead with its share buyback programme, which runs until February 2027. For investors, the picture remains a complex one: a sturdy core operation set against structural doubts about the long-term growth trajectory — doubts that Morgan Stanley's downgrade has now brought into sharper focus.